Stocks Health care SRZN
NASDAQ · Health careSurrozen, Inc. (SRZN)
Surrozen, Inc. brought in $10.5M of revenue over the twelve months to September 30, 2026, up 192.1% from a year earlier. It posted a net loss of $390.2M. In fiscal 2025 capital spending exceeded operating cash flow by $30.4M. At September 30, 2026 it held $100.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Surrozen, Inc.
- Net worth
- Surrozen, Inc. has a market value (market cap) of $391.4M at the latest share price, and shareholders' equity of -$335.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.5M (-67.4% year on year), with a net loss of $242M. Over the 12 months to September 30, 2026: revenue $10.5M, net loss $390.2M.
- Cash flow
- In fiscal 2025 operations used $30.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Surrozen, Inc.'s next report is expected around March 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Surrozen, Inc. does
Surrozen, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SRZN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.5M | -$242M | -$32.37 | -$30.4M |
| 2024 | $10.7M | -$63.6M | -$21.67 | -$17.7M |
| 2023 | $0 | -$43M | -$21.33 | -$40.8M |
| 2022 | $12.5M | -$36M | -$15.56 | -$44.9M |
| 2021 | $0 | -$54.6M | -$33.07 | -$50.1M |
| 2020 | n/a | -$32.7M | n/a | -$30M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SRZN ranks in Health care
Latest SEC filings
What Surrozen, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 6, 2026Activist stake changed SCHEDULE 13D/A
- October 22, 2026Activist stake changed SCHEDULE 13D/A
- October 20, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- October 2, 2026Other event 8-K
- October 1, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Surrozen, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 6 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 20, 2026 | Kutzkey TimDirector, 10% owner | Exercised optionsindirect | 485,830 | $5.6M |
| October 20, 2026 | Kutzkey TimDirector, 10% owner | Exercised optionsindirect | 548,653 | $6.4M |
| October 20, 2026 | Kutzkey TimDirector, 10% owner | Exercised optionsindirect | 517,241 | $6M |
| October 20, 2026 | Column Group III Gp, LP10% owner | Exercised optionsindirect | 485,830 | $5.6M |
| October 20, 2026 | Column Group III Gp, LP10% owner | Exercised optionsindirect | 548,653 | $6.4M |
| October 20, 2026 | Column Group III Gp, LP10% owner | Exercised optionsindirect | 517,241 | $6M |
| July 22, 2026 | TCG Crossover GP II, LLC10% owner | Soldindirect | 162,500 | $3.5M |
| July 22, 2026 | TCG Crossover GP II, LLC10% owner | Soldindirect | 162,500 | $3.5M |
Who owns SRZN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tim Kutzkey13D, may seek influence with 7 related filers | 21.4% | November 6, 2026 |
| Boxer Capital Management, LLC13G, passive with 3 related filers | 11.6% | October 7, 2026 |
| AI Biotechnology LLC13G, passive with 3 related filers | 9.9% | March 31, 2025 |
| Chen Yu13G, passive with 4 related filers | 9.9% | July 24, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 9.9% | May 15, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.2% | February 17, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 8.5% | February 5, 2026 |
| 5AM Partners VII, LLC13G, passive with 3 related filers | 7.8% | August 11, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 7.5% | October 1, 2026 |
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 5.8% | November 14, 2024 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 5.4% | April 23, 2026 |
| StemPoint Capital LP13G, passive with 2 related filers | 5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 69 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| TCG Crossover Management, LLC | 1,473,101 | 0 |
| Boxer Capital Management, LLC | 1,105,683 | +339,365 |
| Kalehua Capital Management LLC | 770,356 | 0 |
| Millennium Management LLC | 683,079 | -48,059 |
| Point72 Asset Management, L.P. | 664,272 | new |
| Venrock Adviser, LLC | 632,931 | 0 |
| Stempoint Capital LP | 602,798 | -118,822 |
| Perceptive Advisors LLC | 503,985 | +274,592 |
| Spruce Street Capital LP | 432,040 | 0 |
| BlackRock, Inc. | 394,864 | +367,013 |
| Vanguard Capital Management LLC | 392,550 | +223,458 |
| Braidwell LP | 390,753 | -5,347 |
| Vestal Point Capital, LP | 304,669 | -33,942 |
| 5AM Venture Management, LLC | 271,250 | -116,250 |
| Vivo Capital, LLC | 260,000 | 0 |
| Balyasny Asset Management L.P. | 205,032 | +1,144 |
| Geode Capital Management, LLC | 201,652 | +135,803 |
| Acuta Capital Partners, LLC | 173,395 | +548 |
| Regents of The University of California | 133,207 | 0 |
| State Street Corp | 133,084 | +105,358 |
Insiders
7 insiders reported holding 2,354,084 shares in total, about $78.4M at the last price.
| Holder | Shares |
|---|---|
| Column Group III Gp, LP10% owner | 862,068862,068 held indirectly |
| Kutzkey TimDirector, 10% owner | 862,068862,068 held indirectly |
| TCG Crossover GP II, LLC10% owner | 574,047574,047 held indirectly |
| Li YangExec. Vice President, Research | 18,882 |
| Williams Charles OChief Operating Officer | 18,237 |
| Parker Craig CChief Executive Officer, Director | 18,175 |
| Maleki Andrew PedrumChief Financial Officer | 607 |
Questions about SRZN
What does Surrozen, Inc. do?
Surrozen, Inc. is a company in the Health care sector, listed on NASDAQ as SRZN. Its shares trade on NASDAQ under the ticker SRZN.
What is Surrozen, Inc.'s net worth?
Surrozen, Inc. has a market value (market cap) of $391.4M at the latest share price, and shareholders' equity of -$335.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Surrozen, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $390.2M on revenue of $10.5M.
How much revenue does Surrozen, Inc. make?
Over the twelve months to September 30, 2026 Surrozen, Inc. reported revenue of $10.5M. That is 192.1% more than a year earlier.
When did Surrozen, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Surrozen, Inc.'s next earnings report?
Surrozen, Inc.'s next report is expected around March 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SRZN with
Follow SRZN
Get an email when Surrozen, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Surrozen, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.